A new indication

Semaglutide approved for reduction of CVD events in overweight and obese patients The TGA has approved semaglutide 2.4 mg (sold as Wegovy) as a complementary therapy for reducing major adverse cardiovascular events, such as cardiovascular death, non-fatal myocardial infarction or non-fatal stroke, in overweight and obese patients with pre-existing heart disease. Its new indication is